| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income (loss) | 937 | 503 | 220 | -1,684 |
| Depreciation and amortization | 742 | 494 | 244 | 790 |
| Impairment of goodwill | 0 | 0 | - | 1,000 |
| Impairment of long-lived assets and assets held for sale | 255 | 177 | 77 | 758 |
| Net change in operating assets and liabilities | 1,595 | 1,035 | 700 | 190 |
| Deferred income taxes net and uncertain tax positions | -76 | -183 | 28 | -666 |
| Stock-based compensation | 106 | 72 | 34 | 89 |
| Other items | 122 | 94 | -8 | 597 |
| Net loss (gain) from sale of business and long-lived assets | 0 | 0 | - | 22 |
| Net cash provided by (used in) operating activities | 491 | 122 | -105 | 672 |
| Beneficial interest collected in exchange for securitized trade receivables | 932 | 658 | 322 | 951 |
| Purchases of property, plant and equipment and intangible assets | 359 | 223 | 127 | 369 |
| Proceeds from sale of business and long-lived assets, net | 34 | 26 | 17 | 39 |
| Acquisition of businesses, net of cash acquired | 0 | 0 | 0 | 15 |
| Purchases of investments and other assets | 40 | 27 | 11 | 56 |
| Proceeds from sale of investments | 0 | - | - | 40 |
| Other investing activities | -5 | -3 | - | 0 |
| Net cash provided by (used in) investing activities | 572 | 437 | 201 | 590 |
| Repayment of senior notes and loans and other long term liabilities | 4,112 | 3,668 | 1,368 | 956 |
| Proceeds from senior notes, net of issuance costs | 2,298 | 2,305 | - | - |
| Proceeds from short term debt | - | - | - | 0 |
| Purchase of shares from redeemable and non-redeemable non-controlling interests | -38 | -38 | -38 | -64 |
| Repayment of short term debt | - | - | - | 0 |
| Dividends paid to redeemable and non-redeemable non-controlling interests | -340 | -340 | -340 | -78 |
| Other financing activities | 1 | 3 | 3 | -19 |
| Net cash provided by (used in) financing activities | -2,191 | -1,738 | -1,744 | -1,117 |
| Translation adjustment on cash and cash equivalents | 31 | 40 | 45 | -53 |
| Net change in cash and cash equivalents | -1,097 | -1,139 | -1,603 | 92 |
| Cash and cash equivalents at beginning of period | 3,300 | 3,300 | 3,300 | 3,227 |
| Cash and cash equivalents at end of period | 2,203 | 2,161 | 1,697 | 3,319 |
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)